For endometrial cancer cells with loss of functional p53 mutation or p53-null mutation, antiangiogenesis inhibitor BIBF1120 substantially increased paclitaxel sensitivity, including in cells that have high baseline resistance to paclitaxel. Here, TP53 is linked to endometrial cancer.